ArticleCurrent pharmaceutical design2024
Encapsulating Rhodamine 6G in Oxidized Sodium Alginate Polymeric Hydrogel for Photodynamically Inactivating Cancer Cells.
Article in Current pharmaceutical design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Metformin in Diabetes and Beyond: Therapeutic Mechanisms, Lactic Acidosis, Organ-Specific Effects, and Nanotechnology-Based Delivery Strategies.Current medical science · 2026Review
- Photodynamic therapy-induced inflammation and adverse effects: An updated review.Biomedical journal · 2026Review
- Iron-doped Zif-8 nanoplatform for MRI-guided synergistic microwave thermal/chemodynamic therapy of triple-negative breast cancer.International journal of pharmaceutics: X · 2025Article
- Review of light activated antibacterial nanomaterials in the second biological window.Journal of nanobiotechnology · 2025Review
- Lipid functionalized silver-coated carbon dot-capped manganese ferrite as drug-free core-shell nanoparticles for multimodal imaging and therapy.ADMET & DMPK · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAs cancer therapy progresses, challenges remain due to the inherent drawbacks of conventional treatments such as chemotherapy, gene therapy, radiation therapy, and surgical removal. Moreover, due to their associated side effects, conventional treatments affect both cancerous and normal cells, making photodynamic therapy (PDT) an attractive alternative.
methodsAs a result of its minimal toxicity, exceptional specificity, and non-invasive characteristics, PDT represents an innovative and highly promising cancer treatment strategy using photosensitizers (PSs) and precise wavelength excitation light to introduce reactive oxygen species (ROS) in the vicinity of cancer cells.
resultsPoor aqueous solubility and decreased sensitivity of Rhodamine 6G (R6G) prevent its use as a photosensitizer in PDT, necessitating the development of oxidized sodium alginate (OSA) hydrogelated nanocarriers to enhance its bioavailability, targeted distribution, and ROS-quantum yield. The ROS quantum yield increased from 0.30 in an aqueous environment to 0.51 when using alginate-based formulations, and it was further enhanced to 0.81 in the case of OSA.
conclusionFurthermore, the nanoformulations produced fluorescent signals suitable for use as cellular imaging agents, demonstrating contrast-enhancing capabilities in medical imaging and showing minimal toxicity.
Indexed as
Identifiers
39108122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.